Maxcyte
MXCT
Maxcyte (MXCT) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.08
- EPS estimate
- −$0.09
- EPS surprise
- +11.11%
- Revenue surprise
- +11.76%
- Revenue
- $7.3M
- Revenue estimate
- $6.5M
- Reported
- Aug 12, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 12, 2026 | −$0.09 | −$0.08 | +11.11% | $7.3M | SEC |
| Q1 2026 | May 12, 2026 | −$0.08 | −$0.04 | +47.23% | $9.7M | SEC |
| Q4 2025 | Mar 24, 2026 | −$0.08 | −$0.09 | −17.96% | $7.3M | SEC |
| Q3 2025 | Nov 5, 2025 | −$0.11 | −$0.12 | −7.24% | $6.8M | SEC |
| Q2 2025 | Aug 6, 2025 | −$0.10 | −$0.12 | −17.99% | $8.2M | SEC |
| Q1 2025 | May 7, 2025 | −$0.10 | −$0.10 | +2.44% | $10.4M | SEC |
| Q4 2024 | Mar 11, 2025 | −$0.12 | −$0.10 | +15.33% | $8.7M | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.12 | −$0.11 | +8.33% | $8.2M | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.12 | −$0.09 | +26.77% | $10.4M | SEC |
| Q1 2024 | May 7, 2024 | −$0.13 | −$0.09 | +28.40% | $11.3M | SEC |
| Q4 2023 | Mar 12, 2024 | −$0.07 | −$0.05 | +25.48% | $15.7M | SEC |
| Q3 2023 | Nov 8, 2023 | −$0.10 | −$0.11 | −9.02% | $8.0M | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.10 | −$0.10 | −4.17% | $9.0M | SEC |
| Q1 2023 | May 10, 2023 | −$0.11 | −$0.11 | +1.79% | $8.6M | SEC |
| Q4 2022 | Mar 15, 2023 | −$0.08 | −$0.05 | +35.48% | $12.4M | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.09 | −$0.06 | +33.33% | $10.6M | SEC |
| Q2 2022 | Aug 10, 2022 | −$0.08 | −$0.08 | −5.26% | $9.6M | SEC |
| Q1 2022 | May 9, 2022 | −$0.07 | −$0.04 | +39.39% | $11.6M | SEC |
| Q4 2021 | Mar 22, 2022 | −$0.06 | −$0.05 | +13.79% | $10.2M | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.06 | −$0.03 | +47.83% | $10.1M | — |
Quarterly revenue
Frequently asked questions
When did Maxcyte (MXCT) last report earnings?
Maxcyte last reported on Aug 12, 2026, covering fiscal Q2 2026.
Did MXCT beat earnings estimates?
Yes. Maxcyte reported EPS of −$0.08 for Q2 2026 against a −$0.09 estimate — a 11.11% beat.
How much revenue did MXCT report last quarter?
Maxcyte reported $7.3M in revenue for Q2 2026, against a consensus estimate of $6.5M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.